Sergio Raposeiras-Roubin1, Xavier Rosselló2, Belén Oliva3, Leticia Fernández-Friera4, José M Mendiguren5, Vicente Andrés6, Héctor Bueno7, Javier Sanz8, Vicente Martínez de Vega9, Emad Abu-Assi10, Andrés Iñiguez10, Antonio Fernández-Ortiz11, Borja Ibáñez12, Valentin Fuster13. 1. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Department of Cardiology, Álvaro Cunqueiro University Hospital, Vigo, Spain. Electronic address: https://twitter.com/Borjaibanez1. 2. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain; Department of Cardiology, Son Espases University Hospital, Palma de Mallorca, Spain. 3. National Center for Cardiovascular Research (CNIC), Madrid, Spain. 4. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain; Comprehensive Cardiovascular Diseases Center, HM Montepríncipe University Hospital, Madrid, Spain. 5. Santander Bank, Madrid, Spain. 6. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain. 7. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain; Health Research Institute, October 12 Hospital (imas12), Madrid, Spain. 8. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA. 9. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Quirón University Hospital, Madrid, Spain. 10. Department of Cardiology, Álvaro Cunqueiro University Hospital, Vigo, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain. 11. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain; Health Research Institute Clínico San Carlos Hospital, Complutense University, Madrid, Spain. 12. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Centro de Investigación Biomédica en Red Consortium for Cardiovascular Diseases (CIBERCV), Madrid, Spain; Health Research Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain. Electronic address: bibanez@cnic.es. 13. National Center for Cardiovascular Research (CNIC), Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: vfuster@cnic.es.
Abstract
BACKGROUND: Even when low-density lipoprotein-cholesterol (LDL-C) levels are lower than guideline thresholds, a residual risk of atherosclerosis remains. It is unknown whether triglyceride (TG) levels are associated with subclinical atherosclerosis and vascular inflammation regardless of LDL-C. OBJECTIVES: This study sought to assess the association between serum TG levels and early atherosclerosis and vascular inflammation in apparently healthy individuals. METHODS: An observational, longitudinal, and prospective cohort study, including 3,754 middle-aged individuals with low to moderate cardiovascular risk from the PESA (Progression of Early Subclinical Atherosclerosis) study who were consecutively recruited between June 2010 and February 2014, was conducted. Peripheral atherosclerotic plaques were assessed by 2-dimensional vascular ultrasound, and coronary artery calcification (CAC) was assessed by noncontrast computed tomography, whereas vascular inflammation was assessed by fluorine-18 fluorodeoxyglucose uptake on positron emission tomography. RESULTS: Atherosclerotic plaques and CAC were observed in 58.0% and 16.8% of participants, respectively, whereas vascular inflammation was evident in 46.7% of evaluated participants. After multivariate adjustment, TG levels ≥150 mg/dl showed an association with subclinical noncoronary atherosclerosis (odds ratio [OR]: 1.35; 95% confidence interval [CI]: 1.08 to 1.68; p = 0.008). This association was significant for groups with high LDL-C (OR: 1.42; 95% CI: 1.11 to 1.80; p = 0.005) and normal LDL-C (OR: 1.85; 95% CI: 1.08 to 3.18; p = 0.008). No association was found between TG level and CAC score. TG levels ≥150 mg/dl were significantly associated with the presence of arterial inflammation (OR: 2.09; 95% CI: 1.29 to 3.40; p = 0.003). CONCLUSIONS: In individuals with low to moderate cardiovascular risk, hypertriglyceridemia was associated with subclinical atherosclerosis and vascular inflammation, even in participants with normal LDL-C levels. (Progression of Early Subclinical Atherosclerosis [PESA]; NCT01410318).
BACKGROUND: Even when low-density lipoprotein-cholesterol (LDL-C) levels are lower than guideline thresholds, a residual risk of atherosclerosis remains. It is unknown whether triglyceride (TG) levels are associated with subclinical atherosclerosis and vascular inflammation regardless of LDL-C. OBJECTIVES: This study sought to assess the association between serum TG levels and early atherosclerosis and vascular inflammation in apparently healthy individuals. METHODS: An observational, longitudinal, and prospective cohort study, including 3,754 middle-aged individuals with low to moderate cardiovascular risk from the PESA (Progression of Early Subclinical Atherosclerosis) study who were consecutively recruited between June 2010 and February 2014, was conducted. Peripheral atherosclerotic plaques were assessed by 2-dimensional vascular ultrasound, and coronary artery calcification (CAC) was assessed by noncontrast computed tomography, whereas vascular inflammation was assessed by fluorine-18 fluorodeoxyglucose uptake on positron emission tomography. RESULTS:Atherosclerotic plaques and CAC were observed in 58.0% and 16.8% of participants, respectively, whereas vascular inflammation was evident in 46.7% of evaluated participants. After multivariate adjustment, TG levels ≥150 mg/dl showed an association with subclinical noncoronary atherosclerosis (odds ratio [OR]: 1.35; 95% confidence interval [CI]: 1.08 to 1.68; p = 0.008). This association was significant for groups with high LDL-C (OR: 1.42; 95% CI: 1.11 to 1.80; p = 0.005) and normal LDL-C (OR: 1.85; 95% CI: 1.08 to 3.18; p = 0.008). No association was found between TG level and CAC score. TG levels ≥150 mg/dl were significantly associated with the presence of arterial inflammation (OR: 2.09; 95% CI: 1.29 to 3.40; p = 0.003). CONCLUSIONS: In individuals with low to moderate cardiovascular risk, hypertriglyceridemia was associated with subclinical atherosclerosis and vascular inflammation, even in participants with normal LDL-C levels. (Progression of Early Subclinical Atherosclerosis [PESA]; NCT01410318).
Authors: Yi Wang; Ying Ni Lin; Li Yue Zhang; Chuan Xiang Li; Shi Qi Li; Hong Peng Li; Liu Zhang; Ning Li; Ya Ru Yan; Qing Yun Li Journal: Ther Adv Chronic Dis Date: 2022-05-01 Impact factor: 4.970
Authors: Henry N Ginsberg; Chris J Packard; M John Chapman; Jan Borén; Carlos A Aguilar-Salinas; Maurizio Averna; Brian A Ference; Daniel Gaudet; Robert A Hegele; Sander Kersten; Gary F Lewis; Alice H Lichtenstein; Philippe Moulin; Børge G Nordestgaard; Alan T Remaley; Bart Staels; Erik S G Stroes; Marja-Riitta Taskinen; Lale S Tokgözoğlu; Anne Tybjaerg-Hansen; Jane K Stock; Alberico L Catapano Journal: Eur Heart J Date: 2021-12-14 Impact factor: 29.983